Aspirin's second wonder

Annemijn Algra, a 23-year-old Dutch medical student, sits at a desk in Oxford in the UK, surrounded by towers of papers. She’s in the famous university city doing a research project.

Her task — to painstakingly examine, pool and evaluate the evidence from more than 200 different observational studies investigating the effect of aspirin on cancer.

“Certainly there was a lot of paper!” she says.

“I started making notes, then I moved to Excel spreadsheets. Eventually I had tables 87 pages long. But I enjoyed doing it because the